Table 1 Comparison of clinical and laboratory variables between type 2 diabetes patients with LDL-c within and above target
n | LDL-c within target (n = 27) | n | LDL-c above target (n = 69) | p | |
|---|---|---|---|---|---|
Male n (%) | 27 | 16 (59.3%) | 69 | 40 (58.0%) | 0.908 |
Age (years) | 27 | 59.8 ± 9.7 | 69 | 58.6 ± 8.8 | 0.571 |
Duration of diabetes* (years) | 22 | 10.0 (3.5–15.3) | 55 | 10.0 (5.0–19.0) | 0.412 |
Cardiovascular disease n (%) | 26 | 7 (26.9%) | 68 | 15 (22.1%) | 0.618 |
Cerebrovascular disease n (%) | 26 | 5 (7.4%) | 68 | 4 (15.4%) | 0.2561 |
Peripheral vascular disease n (%) | 27 | 5 (7.4%) | 68 | 2 (7.7%) | 0.9551 |
Body mass index (Kg/m2) | 20 | 29.9 ± 3.7 | 56 | 30.6 ± 4.8 | 0.553 |
Systolic BP (mmHg) | 24 | 142.0 ± 20.9 | 59 | 141.5 ± 18.3 | 0.928 |
Diastolic BP (mmHg) | 11 | 71.8 ± 12.0 | 26 | 78.2 ± 15.4 | 0.229 |
Waist circumference (M) (cm) | 12 | 102.1 ± 9.5 | 17 | 105.0 ± 11.9 | 0.492 |
Waist circumference (F) (cm) | 3 | 96.0 ± 13.4 | 15 | 98.0 ± 12.7 | 0.438 |
Triglycerides* (mg/dL) | 27 | 146.0 (106.0–295.0) | 69 | 146.0 (108.0–207.5) | 0.300 |
HDL-c (M) (mg/dL) | 16 | 35.2 ± 9.68 | 40 | 41.7 ± 12.4 | 0.064 |
HDL-c (F) (mg/dL) | 11 | 50.5 ± 10.7 | 29 | 46.6 ± 10.2 | 0.301 |
Glucose* (mg/dL) | 22 | 137.0 (108.0–182.3) | 59 | 151.5 (119.0–226.8) | 0.062 |
HbA1c (%) | 18 | 7.8 ± 2.6 | 48 | 8.2 ± 1.6 | 0.538 |
Uric acid (mg/dL) | 21 | 5.1 ± 0.4 | 44 | 4.9 ± 0.2 | 0.656 |
Homocysteine (μmol/L) | 20 | 11.4 ± 1.2 | 55 | 12.2 ± 0.8 | 0.632 |
Statin use n (%) | 20 | 14 (70.0%) | 52 | 30 (57.7%) | 0.337 |
Fibrates use n (%) | 20 | 2 (10%) | 52 | 8 (15.4%) | 0.7161 |
Ezetimibe use n (%) | 20 | 3 (15%) | 51 | 1 (2%) | 0.0651 |
Alcohol drinking n (%) | 8 | 1 (12.5%) | 20 | 7 (35.0%) | 0.3711 |
Smoking n (%) | 21 | 2 (9.5%) | 61 | 7 (11.5%) | 0.8051 |
Hypertension n (%) | 27 | 14 (51.9%) | 68 | 56 (82.4%) | 0.020 |